Peptide-targeted radionuclide therapy for melanoma

Area of Science:

• Oncology
• Radiochemistry
• Molecular Imaging and Therapy

Background:

• Melanoma treatment remains challenging, especially for metastatic and end-stage disease.
• Melanocortin-1 receptor (MC1-R) and melanin are melanoma-specific targets.
• Peptide-targeted radionuclide therapy offers a strategy for targeted cytotoxic radiation delivery.

Purpose of the Study:

• To review recent advances in peptide-targeted radionuclide therapy for melanoma.
• To highlight therapeutic strategies targeting MC1-R and melanin.
• To discuss the potential of this therapy for various stages of melanoma.

Main Methods:

• Review of preclinical studies on radiolabeled peptides targeting MC1-R and melanin.
• Evaluation of specific peptide conjugates such as 188Re-(Arg(11))CCMSH, 177Lu- and 212Pb-labeled DOTA-Re(Arg(11))CCMSH, and 188Re-HYNIC-4B4.
• Assessment of therapeutic efficacies in preclinical melanoma models.

Main Results:

• Radiolabeled peptides targeting MC1-R/melanin demonstrate selective delivery of radiation to melanoma cells.
• Promising therapeutic efficacies observed in preclinical models with agents like 188Re-(Arg(11))CCMSH and others.
• The approach shows potential for sparing normal tissues and organs.

Conclusions:

• Peptide-targeted radionuclide therapy targeting MC1-R and melanin presents an optimistic outlook for melanoma treatment.
• This therapy is a potential adjuvant treatment for metastatic deposits after primary tumor removal.
• It offers a necessary new strategy for end-stage melanoma patients lacking effective options.